Serum biomarker profiles suggest that atopic dermatitis is a systemic disease - 05/04/18
The study was supported by MedImmune (CW435174). |
|
Disclosure of potential conflict of interest: C. A. Bruijnzeel-Koomen has received a research grant from MedImmune. E. Csomor, B. R. Sellman, and M. A. Sleeman are employed by MedImmune; and own stock/stock options in AstraZeneca. T. Mustelin and R. D. May are employed by MedImmune; and own stock/stock options in MedImmune. M. S. de Bruin-Weller serves on the advisory boards of Regeneron/Sanofi and AbbVie; consults for Regeneron/Sanofi; has received grants or has grants pending from Regeneron/Sanofi and AbbVie; and has received payment for development of educational presentations from Regeneron/Sanofi. D. J. Hijnen has received a research grant from MedImmune; serves on the advisory boards of MedImmune, Novartis, and LEO Pharma. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 141 - N° 4
P. 1523-1526 - avril 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?